Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18860010 | 0.70 | SLC6A2 (0.42) | PIK3CDTSHRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9752291 | 0.69 | CHRM2 (0.43) | TSHRLMNA | |
| SCHEMBL1136913 | 0.65 | DRD2 (0.41) | PIK3CDTSHR | |
| SCHEMBL1136910 | 0.65 | DRD2 (0.41) | PIK3CDTSHR | |
| SCHEMBL255185 | 0.63 | KDM4E (0.44) | PIK3CDTSHR | |
| SCHEMBL7384750 | 0.63 | KDM4E (0.52) | PIK3CDTSHR | |
| Hydrochloric Acid SCHEMBL190200 | 0.62 | KDM4E (0.43) | PIK3CDTSHR | |
| SCHEMBL15533433 | 0.61 | GBA1 (0.36) | CA1CA2CA4 | |
| SCHEMBL10043 | 0.61 | — | — | |
| SCHEMBL26129643 | 0.61 | SLC6A2 (0.40) | PIK3CDTSHRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392391-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180155346-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155346-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, TBK1 | PIK3CD 59/4885TSHR 2920/4885SLC6A2 3710/4885 |
| US-10392391-B2 | Compounds useful as inhibitors of ATR kinase | ATR, MAP3K20, TBK1 | PIK3CD 59/4885TSHR 2920/4885SLC6A2 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.